Acasti Pharma is a biopharmaceutical company that is focused on the research, development and commercialization of cardiometabolic prescription drugs using omega-3 (OM3) fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. Co.'s primary product candidate is CaPre, an OM3 phospholipid therapeutic. Co. has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patent portfolio and licensed rights for cardiovascular diseases. The ACST stock yearly return is shown above.
The yearly return on the ACST stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACST annual return calculation with any dividends reinvested as applicable (on ex-dates).
|